Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
作者信息
Horby Peter, Staplin Natalie, Haynes Richard, Landray Martin
机构信息
Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
出版信息
Lancet. 2021 Jul 24;398(10297):300. doi: 10.1016/S0140-6736(21)01422-7.
Abstract
摘要
相似文献
1
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Lancet. 2021 Jul 24;398(10297):300. doi: 10.1016/S0140-6736(21)01422-7.
2
Tocilizumab in Treatment for Patients With COVID-19-Reply.
JAMA Intern Med. 2021 Jul 1;181(7):1019-1020. doi: 10.1001/jamainternmed.2021.0404.
3
Tocilizumab in Treatment for Patients With COVID-19-Reply.
JAMA Intern Med. 2021 Jul 1;181(7):1020-1021. doi: 10.1001/jamainternmed.2021.0407.
4
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.
N Engl J Med. 2021 Apr 15;384(15):1474. doi: 10.1056/NEJMc2100217. Epub 2021 Mar 3.
5
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.
N Engl J Med. 2021 Apr 15;384(15):1473-1474. doi: 10.1056/NEJMc2100217. Epub 2021 Mar 3.
6
Tocilizumab in COVID-19 therapy: who benefits, and how?
Lancet. 2021 Jul 24;398(10297):299. doi: 10.1016/S0140-6736(21)01380-5.
7
Tocilizumab in COVID-19 therapy: who benefits, and how?
Lancet. 2021 Jul 24;398(10297):299-300. doi: 10.1016/S0140-6736(21)01427-6.
8
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.
Clin Microbiol Infect. 2021 Aug;27(8):1177-1178. doi: 10.1016/j.cmi.2021.02.024. Epub 2021 Mar 8.
9
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
10
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.
Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.
引用本文的文献
1
Neutrophil-specific Shp1 loss results in lethal pulmonary hemorrhage in mouse models of acute lung injury.
J Clin Invest. 2024 Oct 1;134(24):e183161. doi: 10.1172/JCI183161.
2
Loss of neutrophil Shp1 produces hemorrhagic and lethal acute lung injury.
bioRxiv. 2024 May 28:2024.05.23.595575. doi: 10.1101/2024.05.23.595575.
3
COVID-19 in the Critically Ill Pregnant Patient.
Crit Care Clin. 2022 Jul;38(3):521-534. doi: 10.1016/j.ccc.2022.01.003. Epub 2022 Jan 10.
4
Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls.
Rheumatol Int. 2022 Mar;42(3):457-467. doi: 10.1007/s00296-021-04965-6. Epub 2021 Sep 13.
本文引用的文献
1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
2
Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients.
Cell Rep Med. 2020 Nov 17;1(8):100144. doi: 10.1016/j.xcrm.2020.100144. Epub 2020 Oct 29.
Zotero 插件